Only the U.S. Senate can say for certain whether Robert Califf will be the next commissioner of the FDA, but the cardiologist is demonstrating some leadership on an agency function that has been a sore spot for many in industry: regulation of combination products, which combine drugs, devices and/or biologic materials.